Shares of Fresenius Medical Care AG & Co. (Pref) (ETR:FME) have been given a consensus rating of “Hold” by the nineteen research firms that are covering the company, MarketBeat.com reports. Ten analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is €90.17 ($107.34).

FME has been the topic of a number of research reports. JPMorgan Chase & Co. set a €95.10 ($113.21) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a research report on Thursday, September 14th. Morgan Stanley set a €90.00 ($107.14) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a research report on Friday, September 15th. Goldman Sachs Group set a €97.00 ($115.48) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Berenberg Bank set a €95.60 ($113.81) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Finally, Deutsche Bank set a €83.00 ($98.81) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the stock a “neutral” rating in a research report on Friday, October 20th.

Shares of Fresenius Medical Care AG & Co. (FME) traded down €0.84 ($1.00) on Friday, reaching €89.36 ($106.38). 608,722 shares of the company’s stock were exchanged, compared to its average volume of 586,763. The company has a market capitalization of $27,980.00 and a price-to-earnings ratio of 21.90. Fresenius Medical Care AG & Co. has a 1 year low of €73.87 ($87.94) and a 1 year high of €92.08 ($109.62).

ILLEGAL ACTIVITY WARNING: “Fresenius Medical Care AG & Co. (Pref) (FME) Receives Average Recommendation of “Hold” from Analysts” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/12/fresenius-medical-care-ag-co-pref-fme-receives-average-recommendation-of-hold-from-analysts-2.html.

About Fresenius Medical Care AG & Co. (Pref)

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.